A billion reasons to celebrate: Expanding access to haemophilia treatment worldwide

Sobi and Sanofi have reached a major milestone in their long-standing partnership with the World Federation of Hemophilia (WFH) - the delivery of 1 billion units of factor replacement therapies through the WFH Humanitarian Aid Program.

The program plays a vital role in expanding access to diagnosis, treatment and care for people with bleeding disorders in underserved parts of the world. It combines donated therapies with training and support, helping build local capacity for diagnosis, treatment and long-term care across more than 100 countries.

This milestone builds on a commitment first made in 2014, when Sobi and Sanofi pledged to donate up to 1 billion international units of factor therapy over the ten-year period 2015 to 2025. Since then, the collaboration has grown into one of the largest long-standing humanitarian efforts in rare disease care.

Haemophilia is a rare, lifelong bleeding disorder that, without proper treatment, can lead to serious complications and reduced quality of life. Despite progress in care, more than 75% of people with haemophilia worldwide still have limited or no access to diagnosis and treatment, particularly in low-resource settings. Through the WFH Humanitarian Aid Program and in collaboration with other partners, donated therapies are helping to address these gaps by providing more consistent treatment for patients who would otherwise have little or no access. 

Reaching 1 billion units is not only a reflection of scale, but of sustained effort and collaboration. It represents years of coordinated work to ensure that medicine reaches patients safely and consistently, while also supporting the development of local healthcare capacity.
 

“Treating and preventing haemophilia requires a holistic approach to care. Our partnership with the WFH Humanitarian Aid Program goes beyond providing treatment. It also supports the development of healthcare systems, medical education and local expertise,” said Lydia Abad-Franch, Head of R&D and Medical Affairs and Chief Medical Officer at Sobi. “We are proud to contribute alongside Sanofi and remain committed to expanding access for people living with haemophilia worldwide.”

Sobi and Sanofi provide therapies for both haemophilia A and haemophilia B through the program and are currently the only companies regularly contributing haemophilia B treatment.
 

A Long-Term Partnership

Over time, this collaboration has helped strengthen care systems by enabling earlier diagnosis, improving clinical knowledge, and ensuring a more stable supply of treatment. For many patients, improved access to treatment supports better management of their condition and can ease some of the day-to-day burden of living with haemophilia.

Sobi and Sanofi have supported the initiative as Founding Visionary Contributors, helping to shape and sustain the WFH Humanitarian Aid Program from the outset. As we reflect on this milestone, our focus remains firmly on the future. Together with Sanofi and WFH, we will continue working to expand access, support healthcare communities, and help realise the vision of treatment for all.